Document is current

Article History

Received: 10 November 2021

Accepted: 7 March 2022

First Online: 17 March 2022

Declarations

:

: Data collection was undertaken in line with the European Pharmaceutical Marketing Research Association guidelines (EphMRA Code of Conduct 2019) and as such it did not require ethics committee approval. The questionnaires used in the Schizophrenia DSP were reviewed and given exemption by the Western Institutional Review Board (reference number: AG8618). The survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 (United States Department of Health & Human Services Summary of the HIPPA Privacy Rule 1996) and the Health Information Technology for Economic and Clinical Health Act legislation (HITECH Act 2009).Using a checkbox, patients provided informed consent to take part in the survey.

: Not applicable. Data were collected in such a way that patients and physicians could not be identified directly. Physician and patient data were pseudo-anonymized. A code was assigned when data were collected. Upon receipt by ARW, data were pseudo-anonymized again to mitigate against tracing them back to the individual. Data were aggregated before being shared with the subscriber and/or for publication.

: AK, DL and CB are employed by Janssen Pharmaceuticals. JS, HB, and SM are employed by Adelphi Real World and declare no additional competing interests.